×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:NUVA

NuVasive Stock Forecast, Price & News

$50.67
+0.48 (+0.96%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$49.47
$51.36
50-Day Range
$46.84
$59.72
52-Week Range
$45.45
$70.76
Volume
981,397 shs
Average Volume
575,572 shs
Market Capitalization
$2.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.78
30 days | 90 days | 365 days | Advanced Chart

Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Stock Forecast (MarketRank)

Overall MarketRank

2.00 out of 5 stars

Medical Sector

596th out of 1,418 stocks

Surgical & Medical Instruments Industry

72nd out of 136 stocks

Analyst Opinion: 3.2Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
NuVasive logo

About NuVasive (NASDAQ:NUVA)

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

NUVA Stock News Headlines

NuVasive (NASDAQ:NUVA) Shares Down 2.4%
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:NUVA
CUSIP
67070410
Employees
2,900
Year Founded
1997

Company Calendar

Last Earnings
5/04/2022
Today
6/24/2022
Next Earnings (Estimated)
7/27/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$63.78
High Stock Price Forecast
$83.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+25.9%
Consensus Rating
Hold
Rating Score (0-4)
2.45454545454545
Research Coverage
11 Analysts

Profitability

Net Income
$-64.09 million
Pretax Margin
-2.28%

Debt

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$4.89 per share
Book Value
$15.37 per share

Miscellaneous

Free Float
51,796,000
Market Cap
$2.64 billion
Optionable
Optionable
Beta
1.11

Social Links















NuVasive Frequently Asked Questions

Should I buy or sell NuVasive stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NuVasive stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View analyst ratings for NuVasive
or view top-rated stocks.

What is NuVasive's stock price forecast for 2022?

11 brokerages have issued twelve-month target prices for NuVasive's shares. Their NUVA stock forecasts range from $54.00 to $83.00. On average, they expect NuVasive's stock price to reach $63.78 in the next year. This suggests a possible upside of 25.9% from the stock's current price.
View analysts' price targets for NuVasive
or view top-rated stocks among Wall Street analysts.

How has NuVasive's stock price performed in 2022?

NuVasive's stock was trading at $52.48 at the beginning of 2022. Since then, NUVA stock has decreased by 3.4% and is now trading at $50.67.
View the best growth stocks for 2022 here
.

When is NuVasive's next earnings date?

NuVasive is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022.
View our earnings forecast for NuVasive
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) released its quarterly earnings results on Wednesday, May, 4th. The medical device company reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.16. The medical device company had revenue of $290.80 million for the quarter, compared to analyst estimates of $277.63 million. NuVasive had a positive trailing twelve-month return on equity of 11.85% and a negative net margin of 3.23%. The company's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the business earned $0.37 EPS.
View NuVasive's earnings history
.

How will NuVasive's stock buyback program work?

NuVasive declared that its board has approved a share buyback plan on Tuesday, November 9th 2021, which permits the company to repurchase $100,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 3.5% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's management believes its shares are undervalued.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive updated its FY 2022 earnings guidance on Wednesday, May, 11th. The company provided earnings per share (EPS) guidance of $2.15-$2.45 for the period, compared to the consensus EPS estimate of $2.17. The company issued revenue guidance of $1.21 billion-$1.23 billion, compared to the consensus revenue estimate of $1.21 billion.

Who are NuVasive's key executives?

NuVasive's management team includes the following people:
  • Mr. J. Christopher Barry, CEO & Director (Age 48, Pay $2.93M) (LinkedIn Profile)
  • Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 52, Pay $939.39k)
  • Mr. Dale A. Wolf, Sr. VP of Global Operations (Age 42, Pay $679.16k)
  • Mr. Nathaniel B. Sisitsky Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 47, Pay $787.93k)
  • Mr. Massimo Calafiore, Exec. VP & Chief Commercial Officer (LinkedIn Profile)
  • Mr. Marc Rosenbaum, VP, Corp. Controller & Chief Accounting Officer (Age 50)
  • Mr. Ryan Donahoe, Sr. VP & Chief Technology Officer
  • Mr. Johnson Lai, Chief Information Officer
  • Ms. Juliet C. Cunningham, VP of Investor Relations
  • Mr. Michael Farrington, Sr. VP of Corp. Marketing, Brand & Communication

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive CEO Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among NuVasive's employees.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

Who are NuVasive's major shareholders?

NuVasive's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.70%), Dimensional Fund Advisors LP (2.59%), Paradice Investment Management LLC (2.41%), Goldman Sachs Group Inc. (2.02%), Loomis Sayles & Co. L P (1.46%) and Fisher Asset Management LLC (1.44%). Company insiders that own NuVasive stock include Gregory T Lucier, James Christopher Barry, Lucas Vitale, Massimo Calafiore, Matthew Link and Paul Mcclintock.
View institutional ownership trends for NuVasive
.

Which institutional investors are selling NuVasive stock?

NUVA stock was sold by a variety of institutional investors in the last quarter, including Pier 88 Investment Partners LLC, Anchor Capital Advisors LLC, Paradice Investment Management LLC, Royal Bank of Canada, The Manufacturers Life Insurance Company , Rothschild & Co. Asset Management US Inc., SG Americas Securities LLC, and Vanguard Group Inc.. Company insiders that have sold NuVasive company stock in the last two years include James Christopher Barry, Lucas Vitale, and Massimo Calafiore.
View insider buying and selling activity for NuVasive
or view top insider-selling stocks.

Which institutional investors are buying NuVasive stock?

NUVA stock was acquired by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., Nuance Investments LLC, Goldman Sachs Group Inc., Leeward Investments LLC MA, Frontier Capital Management Co. LLC, Woodline Partners LP, New York State Common Retirement Fund, and Canada Pension Plan Investment Board.
View insider buying and selling activity for NuVasive
or or view top insider-buying stocks.

How do I buy shares of NuVasive?

Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $50.67.

How much money does NuVasive make?

NuVasive (NASDAQ:NUVA) has a market capitalization of $2.64 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64.09 million in net income (profit) each year or ($0.75) on an earnings per share basis.

How many employees does NuVasive have?

NuVasive employs 2,900 workers across the globe.

Does NuVasive have any subsidiaries?

The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.
Read More

When was NuVasive founded?

NuVasive was founded in 1997.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for NuVasive is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at [email protected], or via fax at 800-475-9134.

This page (NASDAQ:NUVA) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.